Literature DB >> 902377

Comparative hemodynamic effects of inotropic and vasodilator drugs in severe heart failure.

E Mikulic, J N Cohn, J A Franciosa.   

Abstract

In 12 patients with severe congestive heart failure (CHF) due to ischemic heart disease or nonischemic cardiomyopathy the hemodynamic response to intravenous infusion of sodium nitroprusside (N) was compared to that of dobutamine (D) 10 microgram/kg/min. D and N produced comparable increases in cardiac output (CO) (2.8 to 5.8 L/min and 2.9 to 5.0 L/min, respectively), but, compared to N, D caused a higher arterial pressure (99.3 vs 86.2 mm Hg, P less than 0.01) and heart rate (102.5 vs 95.3, P less than 0.05) and less reduction in pulmonary wedge pressure (PWP) (28.9 to 20.2 mm Hg vs 29.1 to 16.6 mm Hg, P less than 0.05). In five additional patients N and D were studied separately and then were infused together. The combination resulted in a higher CO, lower PWP and greater reduction in systemic and pulmonary vascular resistances than either drug alone. Brachial arterial infusion of nitroprusside produced prominent forearm vasodilation in a dose less than 10% of the systemic dose, whereas vasodilation with dobutamine was only modest even when 50% of the systemic dose was infused. Therefore, potent inotropic and vasodilator drugs produce similar and additive augmentation to left ventricular performance in heart failure. Reduction in vascular resistance with dobutamine probably is largely of reflex origin, but the vasodilation itself may be an important determinant of the rise in cardiac output.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 902377     DOI: 10.1161/01.cir.56.4.528

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

Review 1.  The rationale for combined use of diuretics, digitalis, and vasodilators in congestive heart failure.

Authors:  T W Smith; M A Pfeffer
Journal:  Cardiovasc Drugs Ther       Date:  1989-03       Impact factor: 3.727

Review 2.  Vasodilator therapy in the perioperative period.

Authors:  P N Fyman; J E Cottrell; L Kushins; P A Casthely
Journal:  Can Anaesth Soc J       Date:  1986-09

3.  Nitroprusside-epinephrine administration in acute myocardial ischemia.

Authors:  H I Pass; M D Turner; W A Neely; F A Crawford
Journal:  World J Surg       Date:  1983-11       Impact factor: 3.352

4.  Cardiovascular effects of prenalterol on rest and exercise haemodynamics in patients with chronic congestive cardiac failure.

Authors:  A C Tweddel; R G Murray; D Pearson; W Martin; I Hutton
Journal:  Br Heart J       Date:  1982-04

5.  Short- and long-term effects of hydralazine and combined hydralazine-prenalterol therapy in severe chronic congestive heart failure.

Authors:  H Drexler; H Löllgen; H Just
Journal:  Klin Wochenschr       Date:  1981-06-15

6.  Treatment of chronic heart failure with pirbuterol: acute haemodynamic responses.

Authors:  J R Dawson; R Canepa-Anson; P Kuan; N H Whitaker; J Carnie; C Warnes; S R Reuben; P A Poole-Wilson; G C Sutton
Journal:  Br Med J (Clin Res Ed)       Date:  1981-05-02

7.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

8.  Synergistic effects of a combined salbutamol-nitroprusside regimen in acute myocardial infarction and severe left ventricular failure.

Authors:  M B Fowler; A D Timmis; D A Chamberlain
Journal:  Br Med J       Date:  1980-02-16

9.  Treatment of congestive cardiomyopathy.

Authors:  W H Abelmann
Journal:  Postgrad Med J       Date:  1978-07       Impact factor: 2.401

10.  Dose-response relationship in normal subjects of prenalterol, a beta-adrenergic agonist with positive inotropic and resistance lowering effects.

Authors:  S Rasmussen; P F Høilund-Carlsen; B Hesse; O J Hartling; J Fabricius; H Dige-Petersen; J Giese
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.